Orca1

FDA inspection

TAPI Puerto Rico, Inc.: FDA inspection ending Aug 16, 2007

FDA inspection 485153 · Voluntary Action Indicated (VAI) · Guayama, PR

Key facts

Inspection ID 485153
Firm TAPI Puerto Rico, Inc.
FEI number 3001104764
Address State Road # 3 Km. 143.0
City Guayama
State PR
ZIP 00784
Fiscal year 2007
Inspection end date Aug 16, 2007
Classification Voluntary Action Indicated (VAI)
Project area Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation
Product type Drugs

At a glance

  • None Citations
  • 1–9 Posted citations
  • No Warning letter followed
  • Yes Form FDA 483 issued
  • No Establishment inspection report (EIR) exists
  • 10–99 Inspections at this FEI

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

Other inspections at this establishment

About FDA inspections

FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.

Source: U.S. Food and Drug Administration (FDA), inspection classification data

Browse all FDA inspections